Fibrinolytic Treatment of Acute MyocardialInfarction
Authors:
M. Aschermann; J. Horák; V. Řezníček; prof. MUDr. Jan Bělohlávek, Ph.D.; O. Aschermann
Authors‘ workplace:
II. interní klinika 1. LF UK a VFN, Praha
Published in:
Čas. Lék. čes. 2003; : 582-585
Category:
Overview
Direct PTCA is a treatment of choice in patients with acute myocardial infarction with ST segment elevations(STEMI). Fibrinolysis remains important modality of treatment in these patients. Currently, there are more then 100 tissueplasminogen activator mutants available with different fibrin specificity. In a clinical practice, tissue-type plasminogenactivator (t-PA), recombinant tissue-type plasminogen activator (rt-PA), tenecteplase (TNK-tPA) and lanoteplase(n-PA) are most important examples. Fibrinolytic treatment in STEMI patients should be used in patients presenting infirst 4 hours after beginning of chest pain, when it is sure, that direct PTCA cannot be started within next 90 minutes.Concomittant therapy of acute STEMI patients consists of anticoagulans, antiplatelet and antiagregatory treatment.
Key words:
acute myocardial infarction, fibrinolysis, tissue-type plasminogen activator.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- Cell and Tissue Hypoxia – The Role of von Hippel-Lindau Gene and Hypoxia Inducible Factor-1
- Clinical Epidemiology – the Diagnosis
- Transhepatic Cholangioscopy in the Treatment of Choledocholithiasis
- Fibrinolytic Treatment of Acute MyocardialInfarction